Ethical Issues Surrounding Personalized Medicine: A Literature Review
More than a decade ago, personalized medicine was presented in modern medicine. Personalized medicine means that the right drug should be prescribed for the right patient based on genetic data. No doubt is developing medical sciences, and its shift into personalized medicine complicates ethical challenges more than before. In this review, we categorized all probable ethical considerations of personalized medicine in research and development and service provision. Based on our review, extensive changes in healthcare system including ethical changes are needed to overcome the ethical obstacles including knowledge gap and informed consent, privacy and confidentiality and availability of healthcare services. Furthermore social benefit versus science development and individual benefit should be balanced. Therefore guidelines and regulations should be compiled to represent the ethical framework; also ethical decision making should be day-to-day and individualized.
National Institute of Health. Precision Medicine Initiative. (Accessed December 2016,30, at http://www.nih.gov/precisionmedicine).
Annas GJ. Personalized medicine or public health?Bioethics, human rights and choice. Rev Port Saúde Pública 2014;32:158-63.
Delloitte: Achieving the promise of targeted therapies: overcoming the challenges. Targeted Therapies. Deloitte Center for Health Solutions, 4. Deloitte, Washington, DC, USA (2007).
Genomics and personalized medicine. FDA Consumer Magazine. November-December (2005).
Schleidgen S, Marckmann G. Re-focusing the ethical discourse on personalized medicine: a qualitative interview study with stakeholders in the German healthcare system. BMC Med Ethics 2013;14:20.
Green ED, Guyer MS, The National Human Genome Research Institute. Charting a course for genomic medicine from base pairs to bedside. Nature 2011;470:204-13.
Abettan C. Between hype and hope: what is really at stake with personalized medicine? Med Health Care and Philos 2016;19:423-30 .
What happened to personalized medicine? Nature Biotechnol 2012;30:1.
Hedgecoe A, editor. The politics of personalized medicine: pharmacogenetics in the clinic. Cambridge University Press, 2005.
Breckenridge A, Lindpaintner K, Lipton P, McLeod H, Rothstein M, Wallace H. Pharmacogenetics: ethical problems and solutions. Nat Rev Genet 2004;5:676-80.
Bunnik EM, Schermer MHN, Janssens ACJW. Personal genome testing: test characteristics to clarify the discourse on ethical, legal and societal issues. BMC Med Ethics 2011;12:11.
Hansson MG. Taking the patients side: the ethics of pharmacogenetics. Per Med 2010;7:75-85.
Joly Y, Saulnier KM, Osien G, Knoppers BM. The ethical framing of personalized medicine. Curr Opin Allergy Clin Immunol 2014;14:404-8.
Juengst ET, Settersten RA, Fishman JR, McGowan ML.After the revolution? Ethical and social challenges in personalized genomic medicine. Per Med 2012;9:429-39.
Corrigan OP. Pharmacogenetics, ethical issues: a review of the Nuffield Council on Bioethics Report. J Med Ethics 2005;31:144-8.
Daar AS, Singer PA. Pharmacogenetics and geographical ancestry: implications for drug development and global health. Nat Rev Genet 2005;6:241-6.
Petersen KE, Prows CA, Martin LJ, Maglo KN.Personalized medicine, availability and group disparity: an inquiry into how physicians perceive and rate the elements and barriers of personalized medicine. Public Health Genomics 2014;17:209-20.
Browman GP, Vollmann J, Virani A, Schildmann J.Improving the quality of personalized medicine research and practice: through an ethical lens. Per Med 2014;11:413-23.
Corrigan OP, Williams-Jones B. Pharmacogenetics: the bioethical problem of DNA investment banking. Stud Hist Philos Biol Biomed Sci 2006;37:550-65.
Merriman T, Cameron V. Risk-taking: behind the warrior gene story. New Zealand Med J 2007;120:59-62.
Webster A, Martin P, Lewis G, Smart A. Integrating pharmacogenetics into society: in search of a model. Nat Rev Genet 2004;5:663-9.
Morley KI, Hall WD. Using pharmacogenetics in the treatment of psychiatric disorders: some ethical and economic considerations. J Mol Med 2004;82:21-30.
Mordini E. Ethical considerations on pharmacogenomics.Pharmacol Res 2004;49:375-9.
Kalow W. Pharmacogenetics and personalized medicine.Fundam Clin Pharmacol 2002;16:337-42.
Lee SSJ. Personalized medicine and pharmacogenomics:ethical and social challenges. Per Med 2005;2:29-35.
Brothers KB, Rothstein MA. Ethical, legal and social implications of incorporating personalized medicine into healthcare. Per Med 2015;12:43-51.
Haga SB, Beskow LM. Ethical, legal, and social implications of biobanks for genetics research. Adv Genet 2008;60:505-44.
Barry MJ, Edgman-levitan S. Shared decision making.The pinnade of patient-centered care. N Eng J Med 2012;366:780-1.
Sacristán JA. Patient-centered medicine and patient- oriented research: improving health outcomes for individual patients. BMC Med Inform Decis Mak2013;13:6.
Stein D, Terry S. Reforming biobank consent policy: a necessary move away from broad consent toward dynamic consent. Genet Test Med Biomarkers 2013;17:855-6.
Meslin E, Cho M. Research ethics in the era of personalized medicine: updating sciences contract with society. Public Health Genomics 2010;13:378-84.
Hodge JG Jr. Ethical issues conserning genetic testing and screening in public health. Am J Med Genet C Semin Med Genet 2004;125C:66-70.
Corrigan OP. Empty ethics: the problem with informed consent. Sociol Health Illn 2003;25:768-92.
Hansson MG, Dillner J, Bartram CR, Carlsson J, Helgesson G. Should donors be allowed to give broad consent to future biobank research? Lancet Oncoll 2006;7:266-9.
Wolf SM, Lawrenz FP, Nelson CA, et al. Managing incidental findings in human subjects research: analysis and recommendation. J Law Med Ethics 2008;36:219-48.
Stjernschantz Forsberg J, Hansson MG, Eriksson S.Changing perspectives in biobank research-from individual rights to concerns about public health regarding the return of results. Eur J Hum Genet 2009;17:1544-9.
Rotimi CN, Marshall PA. Tailoring the process of informed consent in genetic and genomic research. Genome Med 2010;2:20.
Beskow LM, Friedman JY, Hardy NC, Lin L, Weinfurt KP. Developing a simplified consent form for biobanking. PLoS ONE 2010;8:e21330.
Langanke M, Brothers KB, Erdmann P, Weinert J, Krafczyk-Korth J, Dörr M, et al. Comparing different scientific approaches to personalized medicine: research ethics and privacy protection. Per Med 2011;8:437-44.
Wilcox AJ, Taylor JA, Sharp RR, London SJ. Genetic determinism and the overprotection of human subjects. Nat Rev Genet 1999;21:362.
Robertson JA. Consent and privacy in pharmacogenomic testing. Nat Rev Genet 2001;28:207-9.
Ormond KE, Cho MK. Translating personalized medicine using new genetic technologies in clinical practice: the ethical issues. Per Med 2014;11:211-22.
Offit K, Groeger E, Turner S, Wadsworth EA, Weiser MA. The “duty to warn” a petients family members about hereditary disease risks. JAMA 2004;292:1469-73.
Wagner JK, Mozersky JT, Pyeritz RE. Use it or lose it as an alternative approach to protect genetic privacy in personalized medicine. Urol Oncol 2014;32:198-201.
Knoppers BM. Direct-to-consumer genetic tests and population genome research challenge traditional notions of privacy and consent. EMBO Reports 2010;11:416-9.
Cordeiro JV. Ethical and legal challenges of personalized medicine: paradigmatic examples of research, prevention, diagnosis and treatment. Rev Port Saúde Pública 2014;32:164-80.
Joly Y, Ngueng Feze I, Simard J. Genetic discrimination and life insurance: a systematic review of the evidence. BMC Med 2013;11:25.
Evans JP, Rothschild BB. Return of results: not that complicated? Genet Med 2012;14:358-60.
Green R, Berg J, Grody W, Kalia SS, Korf BR, Martin CL, et al. ACMG recommendadtion for reporting of incidental findings in clinical exome and genome sequencing. Genet Med 2013;15:565-74.
Wolf S, Annas G, Elias S. Point-counterpoint. Patient autonomy and incidental findings in clinical genomics. Science 2013;340:1049-50.
Lolkema MP, Gadellaa-van Hooijdonk CG, Bredenoord AL, Roach N, Cuppen E, et al. Ethical, legal, and
counseling challenges surrounding the return of genetic results in oncology. J Clin Oncol 2013;31:1842-8.
Third Annual Personalized Medicine Meeting. November notes and hand-outs, San Francisco, CA, USA, November
Badzek L, Henaghan M, Turner M, Monsen R. Ethical, legal, and social issues in the translation of genomics into health. J Nurs Scholarsh 2013;45:15-24.
Groves C. Future ethics: risk, care and non-reciprocal responsibility. J Global Ethics 2009;5:17-31.
Wertz DC. Ethical, legal and social issues in pharmacogenomics. Pharmacogenomics J 2003;3:194-6.
Rosenberg NA, Huang L, Jewett EM, Szpiech ZA, Jankovic I, Boehnke M. Genome-wide association studies in diverse populations. Nat Rev Genet 2010;11:356-66.
Maglo KN. Group-based and personalized case in an age of genomic and evidence-based medicine: a reappraisal. Perspect Biol Med 2012;55:137-54.
Kittles R. Genes and environments: moving toward personalized medicine in the context of health disparities. Ethn Dis 2012;22:S1-43-6.
de Vries J, Bull SJ, Doumbo O, Ibrahim M, Mercereau- Puijalon O, Kwiatkowski D, et al. Ethical issues in human genomics research in developing countries. BMC Med Ethics 2011;12:5.
McGlynn E, Asch S, Adams J, Keesey J, Hicks J, DeCristofaro A, et al. The quality of health care delivered to adults in the United States. New Eng J Med 2003;348:2635-45.
|Issue||Vol 55, No 3 (2017)|
|Ethics Personalized medicine Pharmacogenetics studies Genetic data|
|Rights and permissions|
|This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.|